Company Overview - Corbus Pharmaceuticals Holdings Inc. is a clinical-stage company focused on oncology and obesity, committed to innovative scientific approaches to address serious illnesses [5] - The company's pipeline includes CRB-701, a next-generation antibody drug conjugate targeting Nectin-4 on cancer cells; CRB-601, an anti-integrin monoclonal antibody blocking TGFβ activation on cancer cells; and CRB-913, a CB1 receptor inverse agonist for obesity treatment [5] Leadership Changes - Rachelle Jacques has been appointed as Chair of the Board of Directors, effective May 15, succeeding Alan Holmer, who will remain on the Board [1][2] - Rachelle Jacques has over 25 years of leadership experience in biopharmaceuticals, having served in various roles including CEO and board member at multiple biotechnology companies [3][4] Strategic Vision - The company anticipates clinical readouts from all three drugs in its pipeline in the second half of the year, marking a pivotal time for Corbus [2] - Rachelle Jacques emphasized the potential of the company's oncology programs and obesity treatment to drive meaningful change for patients [3]